Abstracts - faqs.org

Abstracts

Pharmaceuticals and cosmetics industries

Search abstracts:
Abstracts » Pharmaceuticals and cosmetics industries

On the selectivity of 7-nitroindazole as an inhibitor of neuronal nitric oxide synthase

Article Abstract:

The ability of nitric oxide synthase (NOS) to inhibit various isoforms of NOS was examined. Assays classified biologic actions as neuronal NOS (nNOS)-mediated or endothelial NOS (eNOS)-dependent. On the basis of these assays, it was asserted that 7-nitroindazole (7-NI) does not exhibit eNOS-mediated cardiovascular effects in vivo. However, recent clinical studies have validated the active role of 7-NI in blood pressure regulation in rats. Further studies should be made to straighten out the in vivo selectivity of 7-NI for nNOS and eNOS.

Author: Reiner, Anton, Zagvazdin, Yuri
Publisher: Elsevier Science Publishers
Publication Name: Trends in Pharmacological Sciences
Subject: Pharmaceuticals and cosmetics industries
ISSN: 0165-6147
Year: 1998
Physiological regulation, Blood pressure, Biological control systems, Blood pressure regulation

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


FLAP: a novel drug target for inhibiting the synthesis of leukotrienes

Article Abstract:

MK0886 is a potent drug derived from indole-3-alkanoic acid that suppresses the synthesis of leukotrienes. The drug exhibits strong affinity to 5-lipoxygenase-activating proteins (FLAP) which upon binding results in the inhibition of 5-lipoxygenase activation. This inhibition involves the translocation of 5-lipoxygenase to the cell membrane which disrupts the progress of cellular leukotriene synthesis.

Author: Ford-Hutchinson, Anthony W.
Publisher: Elsevier Science Publishers
Publication Name: Trends in Pharmacological Sciences
Subject: Pharmaceuticals and cosmetics industries
ISSN: 0165-6147
Year: 1991
Leukotrienes

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Phosphodiesterases: the journey towards therapeutics

Article Abstract:

Researchers discussed the therapeutic use of phosphodiesterase inhibitors at a conference in France in December, 1999. Most research focuses on the use of PDE4 inhibitors as anti-inflammatory agents and PDE5 inhibitors as a treatment for impotence. PDE4 inhibitors may also be beneficial in treating chronic obstructive lung disease.

Author: Torphy, Theodore J., Page, Clive
Publisher: Elsevier Science Publishers
Publication Name: Trends in Pharmacological Sciences
Subject: Pharmaceuticals and cosmetics industries
ISSN: 0165-6147
Year: 2000
Phosphodiesterases

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Research, Enzyme inhibitors
Similar abstracts:
  • Abstracts: Optimizing skin delivery. Exploring marine-derived ingredients for personal care. Chitosan - multi-functional marine polymer
  • Abstracts: The Cosmetic Regulation of Argentina. Regulatory review
  • Abstracts: Changing the countenance of pharmacology courses in medical schools. Pharmacology education in the USA: the role of graduate programs
  • Abstracts: Working from home: freelance medical writing. Careers in pharmaceutical clinical development. Preclinical industrial research
  • Abstracts: Asthma therapy for the 21st century. NF-kB: a pivotal role in asthma and a new target for therapy. Reply: 5-HT(sub)1A receptors and control of airways
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.